Kura Oncology, Inc. (KURA) Stock Ticker
KURA right now
Market factors today
Unlock the full KURA picture
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
KURA stock facts
| Ticker symbol | KURA |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $955.2M |
| CEO | Troy Wilson |
| Employees | 260 |
| Headquarters | San Diego, CA, US |
| IPO date | 2015-09-16 |
| Website | kuraoncology.com |
What you can see for KURA on Tickr
Live KURA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the KURA report.
Rankings
KURA peers
FAQ
What is the ticker symbol for Kura Oncology, Inc.?
The ticker symbol for Kura Oncology, Inc. is KURA, listed on the NASDAQ.
What is KURA?
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted…